• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should Raised Revenue Guidance Require Action From Bausch + Lomb Stock Investors?

    Simply Wall St·11/08/2026 14:26:53
    Listen to the news
    • Bausch + Lomb reported third quarter 2026 revenue of US$1.375b and net income of US$32 million, moving from a loss a year earlier, and modestly raised full year 2026 revenue guidance to US$5.45b to US$5.55b.
    • The shift from a net loss to profit in the quarter, alongside higher guidance, suggests improving operating performance across Bausch + Lomb’s eye care portfolio.
    • We will look at how Bausch + Lomb's investment narrative is affected by the earnings improvement and higher full year revenue guidance.
    Spot 19 high quality undiscovered gems that, like Bausch + Lomb, are using earnings momentum and fresh guidance to reshape expectations.

    Bausch + Lomb Investment Narrative Recap

    To own Bausch + Lomb, you need to believe its eye care portfolio can convert steady demand in dry eye, contact lenses and surgical products into consistent profitability. The recent move to a US$32 million quarterly profit and the raised 2026 revenue range keeps that thesis intact. In the near term, execution on the Vision 27 efficiency program still looks like the key catalyst.

    The biggest current risk is that the group remains loss making for the first nine months of 2026 at US$53 million, so profitability is not yet firmly established. Any slowdown in prescription or premium surgical mix, or weaker cost control, would pressure that margin story in the short term.

    The raised full year 2026 revenue guidance to US$5.45b to US$5.55b is the announcement that matters most here. It directly connects to the revenue led thesis around Bausch + Lomb, across Pharma, Vision Care and Surgical, and links to expectations for stronger operating leverage under Vision 27.

    That slightly higher top line range also sharpens the focus on execution risk. Investors watching catalysts such as dry eye prescriptions, daily silicone hydrogel lens uptake and premium IOL mix can now compare those trends against a clearer revenue yardstick, while still factoring in that the group reported a net loss over the first nine months of 2026.

    Bausch + Lomb's narrative projects US$6.4b revenue and US$344.9 million earnings by 2029. This assumes 5.9% yearly revenue growth and an earnings increase of about US$456 million from current earnings of a US$111.0 million loss.

    Uncover why Bausch + Lomb's fair value indicates a 6% potential upside to its current price. This could narrow quickly if sentiment follows the earnings turn.

    NYSE:BLCO 1-Year Stock Price Chart
    NYSE:BLCO 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the lowest Bausch + Lomb forecasts are surprisingly cautious on R&D payoffs. Before this earnings beat and the board change, those analysts were only pencilling in revenue of about US$6.3b and earnings of US$272.0 million by 2029, so they see pipeline spending as a bigger swing factor. Use that more pessimistic view as a contrast when you weigh how these fresh results and governance moves might reshape expectations.

    Explore 4 other Bausch + Lomb fair value estimates, including one that suggests it could be worth just $21.14.

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking for more Bausch + Lomb style ideas?

    If the Bausch + Lomb story has sharpened your thinking, use that framework to scan for other businesses where earnings momentum, guidance shifts and balance sheet strength are starting to change the conversation.